Structure Therapeutics Inc.

GPCR

Held by 10 specialist biotech funds

High Convergence

Share on X

Fund Holdings

10 fund convergence

Avoro Capital Advisors Deerfield Management OrbiMed Advisors

Position Trend

Feb 17, 2026

$754.0M

9 funds

Mar 16, 2026

$455.9M

1 fund

-40% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Avoro Capital AdvisorsNEWMar 16, 2026

Shares: 6,555,555Value: $455.9M

# Signal Note: Avoro Capital Initiates $456M Position in Structure Therapeutics Avoro's substantial entry signals conviction in GPCR's pipeline, particularly GPCR-A431, an oral GPCR agonist in Phase 2 for NASH where it demonstrated dose-dependent improvements in liver fat content and fibrosis markers in 2024 data. The $456M position (likely 5-7% stake) suggests thesis around near-term Phase 2b readout expected in 2025, which could support accelerated development or partnership validation in a competitive NASH space. Timing aligns with increased GLP-1 off-label NASH interest, creating potential value inflection if GPCR-A431 shows differentiation on fibrosis progression.

Deerfield ManagementNEW

More GPCR Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

NBIX4 funds PHVS4 funds ALKS3 funds IRON3 funds BCRX3 funds NGNE3 funds PRAX3 funds ALNY

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

Deerfield's $53.4M initiation in Structure Therapeutics signals conviction in GPCR drug development, likely centered on GPCR modulation for metabolic diseases where the company has advanced clinical programs. The entry by a sophisticated healthcare investor with multi-strategy expertise suggests confidence in upcoming clinical readouts or regulatory milestones that could validate the platform's differentiation versus competitors in the crowded GLP-1/obesity space.